dc.contributor
Institut Català de la Salut
dc.contributor
[Barrabés JA, Inserte J, Sambola A, Uribarri A, Aluja D, Rodríguez-Palomares JF, García del Blanco B, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Castellote L] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Buera I, Milà I, Vidal M, Delgado-Tomás S] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Tobías-Castillo PE, Calvo-Barceló M] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Guala A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid Spain. [Beneítez D] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Buera Surribas, Irene
dc.contributor.author
Mila Pascual, Laia
dc.contributor.author
Delgado Tomás, Sara
dc.contributor.author
Tobías-Castillo, Pablo Eduardo
dc.contributor.author
Barrabés, José A.
dc.contributor.author
Inserte, Javier
dc.contributor.author
Castellote Bellés, Laura
dc.contributor.author
Sambola Ayala, Antonia
dc.contributor.author
Uribarri, Aitor
dc.contributor.author
Vidal Burdeus, Maria
dc.contributor.author
Aluja, David
dc.contributor.author
Calvo-Barceló, Maria
dc.contributor.author
Guala, Andrea
dc.contributor.author
Rodríguez Palomares, José F
dc.contributor.author
García del Blanco, Bruno
dc.contributor.author
Beneitez Pastor, David
dc.contributor.author
Ferreira-Gonzalez, Ignacio
dc.date.accessioned
2025-09-30T02:07:21Z
dc.date.available
2025-09-30T02:07:21Z
dc.date.issued
2025-08-05T11:46:18Z
dc.date.issued
2025-08-05T11:46:18Z
dc.date.issued
2025-06-03
dc.identifier
Barrabés JA, Inserte J, Castellote L, Buera I, Milà L, Sambola A, et al. Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST‐Segment–Elevation Myocardial Infarction: Influence of the Definition Used. J Am Heart Assoc. 2025 Jun 3;14(11):e040845.
dc.identifier
http://hdl.handle.net/11351/13486
dc.identifier
10.1161/JAHA.124.040845
dc.identifier
001501280900001
dc.identifier.uri
http://hdl.handle.net/11351/13486
dc.description.abstract
Acute myocardial infarction; Iron deficiency; Reperfusion
dc.description.abstract
Infarto agudo de miocardio; Deficiencia de hierro; Reperfusión
dc.description.abstract
Infart agut de miocardi; Deficiència de ferro; Reperfusió
dc.description.abstract
Background
The role of iron deficiency (ID) in ST‐segment–elevation myocardial infarction (STEMI) remains unclear. This study aimed to assess whether ID is associated with impaired myocardial reperfusion in STEMI and whether this association is affected by ID definition.
Methods
We included 942 consecutive patients with STEMI successfully treated with primary percutaneous coronary intervention. ID was defined either as recommended by international guidelines or, alternatively, as ferritin <100 ng/mL, transferrin saturation <20%, or serum iron ≤13 μmol/L. In 595 patients, serum soluble transferrin receptor levels were measured. Impaired myocardial reperfusion was defined as lack of ST‐segment resolution ≥50% 60 to 90 minutes after percutaneous coronary intervention.
Results
ID prevalence varied across these definitions. Impaired reperfusion was present in 12.7% of patients without ID and 41.0% of those with ID defined by transferrin saturation <20% (P<0.001). This association was less pronounced for serum iron ≤13 μmol/L, weaker for guideline criteria, and absent for high (≥1.59 mg/L) soluble transferrin receptor levels or low ferritin. Transferrin saturation <20%, but not ferritin‐based criteria, was associated with poorer clinical course and left ventricular function and higher in‐hospital mortality and remained an independent predictor of impaired reperfusion after adjusting for baseline predictors and anemia.
Conclusions
ID defined by transferrin saturation <20% is strongly related to impaired ST resolution and predicts a worse in‐hospital outcome in patients with STEMI treated with primary percutaneous coronary intervention. The association of other ID criteria with myocardial reperfusion or with the clinical course is weaker or absent. The potential preventive or therapeutic strategies targeting ID in STEMI warrant further investigation.
dc.description.abstract
This study was funded by Instituto de Salud Carlos III, Spain, through the projects AES PI16/00232 and AES PI23/00068 and the research network CIBERCV (CB16/11/00479), both co‐funded by European Regional Development Fund, and by the Sociedad Española de Cardiología y Fundación Española del Corazón (SEC/FEC‐INV‐BAS 23/11).
dc.format
application/pdf
dc.relation
Journal of the American Heart Association;14(11)
dc.relation
https://doi.org/10.1161/JAHA.124.040845
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00232
dc.relation
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI23%2F00068
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F11%2F00479
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Infart de miocardi
dc.subject
Dèficit de ferro
dc.subject
Artèries coronàries - Cirurgia
dc.subject
DISEASES::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction::ST Elevation Myocardial Infarction
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Acute-Phase Proteins::Transferrin
dc.subject
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hypochromic::Anemia, Iron-Deficiency
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Vascular Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention
dc.subject
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio::infarto de miocardio con elevación del ST
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::proteínas de fase aguda::transferrina
dc.subject
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hipocrómica::anemia ferropénica
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::procedimientos quirúrgicos vasculares::procedimientos endovasculares::cirugía coronaria percutánea
dc.title
Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST‐Segment–Elevation Myocardial Infarction: Influence of the Definition Used
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion